114M0 First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3

Patients (pts) with unresectable locally advanced non-small cell lung cancer (laNSCLC) who are not candidates for concurrent chemoradiation have often been excluded from immunotherapy trials, and their care represent an unmet medical need. We report post hoc analyses of pts with laNSCLC who received cemiplimab (anti–programmed cell death-1) from two phase III clinical trials with long-term data.